Paul Mead is the founder of CorFlow Therapeutics AG. CorFlow Therapeutics AG has raised $60M in total funding. Latest round: Series B.
Paul Mead is the President and CEO of CorFlow Therapeutics AG. The company recently completed a €44 million Series B financing round to advance its novel diagnostic and drug delivery platform for microvascular obstruction in heart attack patients. Under his leadership, the company plans an International Pivotal trial to diagnose MVO and a randomized controlled trial to evaluate therapeutic treatments.
Full founder directory · Investor directory · Company funding database · Fundraising library